{
  "pmcid": "12194630",
  "sha256": "0ec2a9fa3555b074cc0782674baf62873b9134b61b2e1ab1c357d7f63a22c0a3",
  "timestamp_utc": "2025-11-09T22:18:17.666789+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.349130434782612,
    "reading_ease": 19.496884057971045,
    "word_count": 230
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Bariatric and Endoscopic Interventions on MASLD"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A randomised controlled trial was conducted with participants meeting obesity criteria and MASLD diagnosis."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were recruited from a tertiary care center."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), adjustable gastric banding (AGB), or endoscopic therapies like intragastric balloon (IGB) and endoscopic sleeve gastroplasty (ESG). The control group received standard lifestyle modification."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the effectiveness of bariatric and endoscopic interventions on metabolic dysfunction-associated steatotic liver disease (MASLD)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the resolution of hepatic steatosis, measured over 12 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "200 participants were randomised: 50 to RYGB, 50 to VSG, 50 to AGB, and 50 to endoscopic therapies."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 48 in RYGB, 47 in VSG, 46 in AGB, and 45 in endoscopic therapies, using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "RYGB showed the highest resolution of steatosis (95%), followed by VSG (60%), AGB (42%), and endoscopic therapies (notable short-term improvements)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in RYGB and 1% in VSG experiencing gastrointestinal side effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Institutes of Health."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}